Sanofi is closer to selling a 50% controlling stake in the consumer health business, Opella to private equity Clayton ...

Sanofi could be "bit more" active with M&A in near future, CFO says Sanofi's R&D spending to see limited increase in 2025 Beyfortus sales double, Dupixent sales miss estimates Jan 30 - Sanofi ...

Merilog’s approval comes as the insulin space has over the past year suffered several setbacks, including strong calls for ...

Sanofi said this morning that its pipeline includes 12 potential blockbuster drugs that could generate more than €10 billion ($11 billion) in annual sales by the end of the decade, a sharp ...

Sanofi has removed (PDF) a clutch of programs from its clinical pipeline, scratching out entries for its late-phase BTK inhibitor and phase 1 prospects linked to the multibillion-dollar takeovers ...

PARIS – L’Oréal has agreed to sell about 29.6 million Sanofi shares to Sanofi for approximately 3 billion euros. The transaction is to be priced at 101.50 euros per share, the French beauty ...

Sanofi has bought back a €3bn ($3.1bn) stake held by cosmetics giant L'Oréal, the first of multiple share buybacks the French drugmaker has planned for 2025. L'Oréal was selling 29,556,650 ...

-Sanofi said on Thursday it would buy back 5 billion euros ($5.21 billion) in shares this year and could be more active with acquisitions in the near term as the drugmaker moves towards selling a ...